Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...

We recently published a list of 10 Firms Heavily Hit by Market Pessimism. In this article, we are going to take a look at ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...

Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...

Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~25% in the premarket on Tuesday as the company disclosed the death of a patient treated with Elevidys, its FDA-approved treatment for ...

The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (BMV:SRPT) with a Sector Perform recommendation. There are 956 funds or institutions reporting positions ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the firm ...

U.S. stocks traded lower midway through trading, with the S&P 500 falling around 1% on Tuesday. The Dow traded down 0.81% to ...